Delayed
Nasdaq
12:35:35 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
1.15
USD
|
0.00%
|
|
-4.58%
|
-49.11%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
433.3
|
436.6
|
152.6
|
78.5
|
-
|
-
|
Enterprise Value (EV)
1 |
433.3
|
206.3
|
156.9
|
105.1
|
48.75
|
-2.709
|
P/E ratio
|
-5.53
x
|
-2.85
x
|
-1.29
x
|
-0.74
x
|
-0.82
x
|
-0.91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
54.9
x
|
7.85
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
34.1
x
|
-0.27
x
|
EV / EBITDA
|
-
|
-2.27
x
|
-1.28
x
|
-0.87
x
|
-0.32
x
|
0.01
x
|
EV / FCF
|
-5.93
x
|
-2.2
x
|
-1.55
x
|
-0.87
x
|
-0.37
x
|
0.03
x
|
FCF Yield
|
-16.9%
|
-45.4%
|
-64.6%
|
-115%
|
-270%
|
3,683%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,290
|
65,649
|
67,806
|
68,260
|
-
|
-
|
Reference price
2 |
11.62
|
6.650
|
2.250
|
1.150
|
1.150
|
1.150
|
Announcement Date
|
14/03/22
|
23/03/23
|
20/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
1.429
|
10
|
EBITDA
1 |
-
|
-
|
-
|
-90.89
|
-122.5
|
-121.3
|
-150.8
|
-189.7
|
EBIT
1 |
-10.42
|
-43.37
|
-69.02
|
-93.42
|
-126
|
-120
|
-123.7
|
-123.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-8,655.69%
|
-1,234.47%
|
Earnings before Tax (EBT)
1 |
-
|
-43.34
|
-68.9
|
-92.09
|
-117.9
|
-114
|
-114.5
|
-123.5
|
Net income
1 |
-
|
-49.26
|
-70.13
|
-92.09
|
-117.9
|
-114
|
-114.5
|
-123.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-8,012.64%
|
-1,234.68%
|
EPS
2 |
-109.8
|
-230.6
|
-2.100
|
-2.330
|
-1.750
|
-1.555
|
-1.396
|
-1.266
|
Free Cash Flow
1 |
-
|
-
|
-73.04
|
-93.61
|
-101.4
|
-120.3
|
-131.7
|
-99.8
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-9,221.04%
|
-997.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/11/20
|
25/03/21
|
14/03/22
|
23/03/23
|
20/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.31
|
-22.8
|
-21.79
|
-24.1
|
-24.72
|
-30.42
|
-32.17
|
-35.32
|
-28.12
|
-32.33
|
-28.6
|
-27.92
|
-27.93
|
-23.12
|
-24
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-18.25
|
-22.74
|
-21.66
|
-23.79
|
-23.91
|
-28.43
|
-29.98
|
-33.19
|
-26.26
|
-30.8
|
-27.43
|
-26.62
|
-26.51
|
-23.12
|
-24
|
Net income
1 |
-18.25
|
-22.74
|
-21.66
|
-23.79
|
-23.91
|
-28.43
|
-29.98
|
-33.19
|
-26.26
|
-30.8
|
-27.43
|
-26.62
|
-26.51
|
-23.12
|
-24
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4900
|
-0.6100
|
-0.5800
|
-0.6300
|
-0.5300
|
-0.4300
|
-0.4500
|
-0.4900
|
-0.3900
|
-0.4500
|
-0.4069
|
-0.3800
|
-0.3466
|
-0.3300
|
-0.3380
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
23/03/23
|
11/05/23
|
10/08/23
|
07/11/23
|
20/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
4.3
|
26.6
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
230
|
-
|
-
|
29.8
|
81.2
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.0351
x
|
-0.219
x
|
-
|
-
|
Free Cash Flow
1 |
-
|
-73
|
-93.6
|
-101
|
-120
|
-132
|
-99.8
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
4.16
|
3.89
|
8.46
|
1.07
|
4.66
|
4.52
|
5.06
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
316.19%
|
50.58%
|
Announcement Date
|
25/03/21
|
14/03/22
|
23/03/23
|
20/03/24
|
-
|
-
|
-
|
Last Close Price
1.15
USD Average target price
14.06
USD Spread / Average Target +1,122.83% Consensus |
1st Jan change
|
Capi.
|
---|
| -49.11% | 78.5M | | +21.03% | 46.93B | | +37.63% | 39.08B | | -8.14% | 38.48B | | +29.25% | 31.01B | | -13.75% | 26.14B | | +10.72% | 25.88B | | +36.29% | 12.53B | | -6.98% | 11.36B | | -12.60% | 10.65B |
Other Biotechnology & Medical Research
|